Compare Johnson & Johnson (JNJ) vs Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Johnson & Johnson trades at $250.38 (market cap $598.96B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.63. The key difference: Johnson & Johnson pays a 2.15% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none, and Johnson & Johnson is trading nearer its 52-week high, Roundhill Innov-100 0DTE Covered Call Strat ETF nearer its low. Which is the better fit depends on your goals.
| JNJ | QDTE | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Income / Options Overlay |
52-Week High | $267.24 | $36.60 |
52-Week Low | $164.36 | $26.85 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
QDTE (Roundhill Innovation-100 0DTE Covered Call Strategy ETF) trades at $29.22, up 0.31% on the day, while technical indicators signal a bearish trend with strong sell signals from moving averages. The ETF generates weekly dividends, with recent payouts ranging from $0.12 to $0.28, but financial ratios like P/E and P/S are unavailable. News highlights focus on its high distribution yield amid declining volatility, with comparisons to peers like XDTE.
Outlook remains cautious due to bearish technicals and fee concerns, though the weekly income strategy appeals to yield-seeking investors. Risks include sensitivity to market volatility and competitive pressure from other income ETFs. Investors should weigh the high yield against potential capital erosion from covered call strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Roundhill Innov-100 0DTE Covered Call Strat ETF
QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →
